...
机译:中度至严重的特应性皮炎的长期管理与杜帕米布和伴随的局部皮质类固醇(Liberty Ad Chronos):1年,随机,双盲,安慰剂控制,第3期试验
Oregon Med Res Ctr Portland OR USA;
Univ Med Ctr Utrecht Utrecht Netherlands;
Queens Univ SKiN Ctr Dermatol Peterborough ON Canada;
Modern Dermatol &
Modern Res Associates Dallas TX USA;
Adv Med Res PC Atlanta GA USA;
Eastern Virginia Med Sch Norfolk VA 23501 USA;
Oregon Hlth &
Sci Univ Portland OR 97201 USA;
K Papp Clin Res &
Prob Med Res Waterloo ON Canada;
Univ British Columbia Dept Dermatol &
Skin Sci Surrey BC Canada;
Australian Natl Univ Phillip ACT Australia;
Univ Melbourne Parkville Vic Australia;
Erasmus Univ Med Ctr Rotterdam Rotterdam Netherlands;
Univ Manchester Dermatol Ctr Salford Royal Hosp Manchester Acad Hlth Sci Ctr Manchester Lancs;
Tokyo Teishin Postal Serv Agcy Hosp Tokyo Japan;
La Paz Univ Hosp Dept Dermatol Madrid Spain;
Hosp del Mar Dept Dermatol Barcelona Spain;
Dept Dermatol Venereol &
Allergol Wroclaw Poland;
Dermatol &
Venereol Hradec Kralove Czech Republic;
Univ Szeged Dept Dermatol &
Allergol Szeged Hungary;
Regeneron Pharmaceut Inc Basking Ridge NJ USA;
Regeneron Pharmaceut Inc 777 Old Saw Mill River Rd Tarrytown NY 10591 USA;
Sanofi Cambridge MA USA;
Regeneron Pharmaceut Inc 777 Old Saw Mill River Rd Tarrytown NY 10591 USA;
Sanofi Chilly Mazarin France;
Regeneron Pharmaceut Inc 777 Old Saw Mill River Rd Tarrytown NY 10591 USA;
Regeneron Pharmaceut Inc 777 Old Saw Mill River Rd Tarrytown NY 10591 USA;
Sanofi Bridgewater NJ USA;
Regeneron Pharmaceut Inc 777 Old Saw Mill River Rd Tarrytown NY 10591 USA;
Regeneron Pharmaceut Inc 777 Old Saw Mill River Rd Tarrytown NY 10591 USA;
Regeneron Pharmaceut Inc 777 Old Saw Mill River Rd Tarrytown NY 10591 USA;
机译:中度至严重的特应性皮炎的长期管理与杜帕米布和伴随的局部皮质类固醇(Liberty Ad Chronos):1年,随机,双盲,安慰剂控制,第3期试验
机译:中度至严重的特应性皮炎的长期管理与杜帕里姆(Dupilumab)和伴随的局部皮质类固醇(Liberty Ad Chronos):批判性评估
机译:Dupilumab具有伴随局部皮质类固醇治疗的成人,具有特应性皮炎,对Ciclosporin A或Inthine治疗的不耐受性:在医学上不可行:安慰剂控制的随机期III III临床试验(LibertyAdcaféLibertyAdcafé)
机译:Dupilumab通过良好控制的几周测量的具有中度至严重的特征性皮炎的成年人中的长期疾病控制:来自自由AD Chronos临床试验的结果
机译:中度至严重的特应性皮炎的长期管理与杜帕米布和伴随的局部皮质类固醇(Liberty Ad Chronos):1年,随机,双盲,安慰剂控制,第3期试验